Study of WJB001 combined therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a body mass index (BMI) of 18.5 or higher.
- You must have an advanced solid tumor, confirmed by previous lab tests, and your tumor tissue must show high levels of a protein called CCNE1.
- Your cancer must have progressed after standard treatments, or no standard treatments are available.
- If you have ovarian, fallopian tube, peritoneal, or uterine serous cancer, you must have either platinum-sensitive or platinum-resistant recurrent disease.
- You must be able to perform daily activities with little or no help (ECOG score 0 or 1) and have adequate blood counts and organ function.
- You cannot have had certain other cancer treatments, live vaccines, or significant heart, bleeding, or immune issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This early-stage trial tests a new drug called JH021 in people with advanced cancer that has stopped responding to standard treatments. The drug may help patients with certain lung cancers (NSCLC with specific EGFR mutations) or other solid tumors grow back after other therapies have failed.
This early-phase study tests whether WJB001 capsules can treat advanced solid tumors in adults whose cancer has progressed after standard treatment (or who cannot take standard treatment). It also studies side effects and whether the drug can work for certain tumor types and genetic markers.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.